Your browser is no longer supported. Please, upgrade your browser.
ARVN Arvinas, Inc. monthly Stock Chart
Arvinas, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own9.60% Shs Outstand39.06M Perf Week4.31%
Market Cap925.65M Forward P/E- EPS next Y-3.35 Insider Trans0.33% Shs Float34.82M Perf Month10.40%
Income-98.80M PEG- EPS next Q-0.79 Inst Own91.10% Short Float18.98% Perf Quarter-6.74%
Sales24.50M P/S37.78 EPS this Y72.20% Inst Trans1.02% Short Ratio13.51 Perf Half Y-25.84%
Book/sh5.25 P/B4.61 EPS next Y-20.10% ROA-35.30% Target Price- Perf Year-36.98%
Cash/sh6.50 P/C3.72 EPS next 5Y- ROE-47.00% 52W Range19.68 - 61.57 Perf YTD-41.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.70% Beta-
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low22.97% ATR1.37
Employees133 Current Ratio6.50 Sales Q/Q-74.80% Oper. Margin- RSI (14)53.85 Volatility4.45% 5.84%
OptionableYes Debt/Eq0.00 EPS Q/Q-46.20% Profit Margin- Rel Volume1.10 Prev Close24.84
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume489.33K Price24.20
Recom1.80 SMA203.58% SMA502.55% SMA200-29.95% Volume539,288 Change-2.58%
Jun-01-20Upgrade Citigroup Neutral → Buy $45
May-12-20Initiated Oppenheimer Perform
Dec-19-19Initiated H.C. Wainwright Buy $50
Nov-25-19Initiated Guggenheim Buy $50
Oct-24-19Upgrade Goldman Neutral → Buy $23 → $38
Sep-25-19Initiated Wedbush Outperform $38
Sep-12-19Initiated BMO Capital Markets Outperform
Aug-06-19Initiated Cantor Fitzgerald Overweight $42
Jun-05-19Downgrade Citigroup Buy → Neutral $21 → $22
Apr-12-19Initiated Evercore ISI Outperform
Oct-22-18Initiated Piper Jaffray Overweight $23
Oct-22-18Initiated Goldman Neutral $17
Oct-22-18Initiated Citigroup Buy $21
Nov-25-20 07:00AM  
Nov-16-20 09:21AM  
Nov-07-20 07:43AM  
Nov-05-20 07:00AM  
Oct-14-20 07:00AM  
Oct-06-20 05:17PM  
Sep-15-20 11:42AM  
Sep-04-20 07:00AM  
Aug-07-20 07:00AM  
Aug-04-20 09:05AM  
Jul-30-20 08:45AM  
Jul-27-20 12:31PM  
Jul-20-20 12:15PM  
Jun-29-20 04:30PM  
Jun-17-20 07:00AM  
Jun-15-20 09:48AM  
Jun-11-20 07:00AM  
Jun-05-20 12:00PM  
May-29-20 10:28AM  
May-20-20 04:30PM  
May-14-20 12:33PM  
May-13-20 05:49PM  
May-12-20 08:54AM  
May-05-20 12:00PM  
May-01-20 06:33AM  
Apr-28-20 09:37AM  
Apr-18-20 10:02AM  
Apr-13-20 04:54PM  
Mar-31-20 07:00AM  
Mar-20-20 11:30AM  
Mar-19-20 08:56AM  
Mar-18-20 06:52AM  
Mar-16-20 08:15AM  
Feb-17-20 12:00PM  
Jan-31-20 09:31AM  
Jan-29-20 06:51AM  
Jan-17-20 05:37AM  
Dec-19-19 06:27PM  
Nov-27-19 07:30AM  
Nov-26-19 08:06AM  
Nov-25-19 11:40AM  
Nov-21-19 07:30AM  
Nov-17-19 12:44PM  
Nov-06-19 09:40PM  
Nov-05-19 09:00AM  
Nov-04-19 05:00PM  
Oct-31-19 11:50AM  
Oct-30-19 09:36AM  
Oct-23-19 07:54AM  
Oct-20-19 08:08AM  
Oct-19-19 09:02AM  
Oct-17-19 07:00AM  
Oct-02-19 07:00AM  
Oct-01-19 02:54PM  
Sep-25-19 02:44PM  
Aug-27-19 07:00AM  
Aug-16-19 12:46PM  
Aug-07-19 07:00AM  
Aug-05-19 07:00AM  
Jul-31-19 01:48PM  
Jul-29-19 07:00AM  
Jul-25-19 07:00AM  
Jul-18-19 07:00AM  
Jun-27-19 06:54AM  
Jun-26-19 06:28PM  
Jun-25-19 07:00AM  
Jun-20-19 08:30AM  
Jun-06-19 07:00AM  
Jun-04-19 07:00AM  
May-29-19 07:00AM  
May-11-19 01:30PM  
May-08-19 07:00AM  
Apr-02-19 07:00AM  
Mar-26-19 07:00AM  
Mar-25-19 07:00AM  
Mar-16-19 09:16AM  
Feb-07-19 04:30PM  
Feb-01-19 12:08PM  
Jan-04-19 05:00PM  
Dec-07-18 07:00PM  
Nov-20-18 06:00AM  
Oct-23-18 07:30AM  
Oct-03-18 08:15PM  
Sep-27-18 10:42AM  
Sep-26-18 08:06PM  
Sep-22-18 04:15PM  
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cassidy Sean AChief Financial OfficerNov 09Option Exercise16.003,00648,096154,784Nov 12 06:00 PM
Kennedy Edward Moore Jr.DirectorNov 09Buy23.998,333199,90942,718Nov 12 06:05 PM
Peck RonaldChief Medical OfficerAug 14Sale27.461,25634,4902,754Aug 18 07:00 PM
SHANNON TIMOTHY MDirectorJun 17Buy30.262,00060,52079,546Jun 19 05:00 PM
SHANNON TIMOTHY MDirectorJun 02Buy32.303,00096,90077,546Jun 04 09:00 PM
SHANNON TIMOTHY MDirectorMay 26Option Exercise22.0612,923285,08174,546May 26 07:05 PM
Ratcliffe LiamDirectorMay 26Option Exercise22.066,500143,3906,500May 27 06:34 PM
Cassidy Sean AChief Financial OfficerMay 13Option Exercise16.001,35621,696151,778May 14 09:30 PM
Cassidy Sean AChief Financial OfficerMay 12Sale60.0010,000600,000150,422May 14 09:25 PM
Morrison BriggsDirectorMar 24Buy38.182,50095,45029,520Mar 25 04:45 PM
Houston John GPresident and CEOMar 23Option Exercise16.006,250100,000816,200Mar 24 07:48 PM
Cassidy Sean AChief Financial OfficerMar 23Option Exercise16.008,030128,480160,422Mar 24 07:30 AM
SHANNON TIMOTHY MDirectorMar 20Buy40.002,500100,00061,623Mar 23 07:01 PM
Houston John GPresident and CEOMar 19Sale37.615,405203,282809,950Mar 23 09:55 PM
Taylor IanChief Scientific OfficerMar 19Sale37.6182631,06670,398Mar 23 09:45 PM
Cassidy Sean AChief Financial OfficerMar 19Sale37.611,51456,942152,392Mar 23 09:35 PM
Margus Bradley AlbertDirectorMar 18Sale37.4640,0001,498,40059,463Mar 20 05:30 PM
Cassidy Sean AChief Financial OfficerFeb 07Sale51.0210,000510,157149,115Feb 11 06:00 PM
Taylor IanChief Scientific OfficerJan 28Option Exercise16.0013,042208,67268,538Jan 30 06:00 PM
Houston John GPresident and CEODec 17Option Exercise16.0012,500200,000797,844Dec 19 04:59 PM